Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2

Free Radical Biology and Medicine

Volumn 43, Issue 9, 2007, Pages 1313-1321

  White, Shai J ^a   Kasman, Laura M ^a   Kelly, Margaret M ^b   Lu, Ping ^a   Spruill, Laura ^a   McDermott, Paul J ^a   Voelkel Johnson, Christina ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apoptosis; c FLIP (cellular FLICE inhibitory protein); Cancer; Doxorubicin; Elongation factor 2; Hydrogen peroxide; Translation

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DOXORUBICIN; ELONGATION FACTOR 2; FLICE INHIBITORY PROTEIN; HLA DR5 ANTIGEN; HYDROGEN PEROXIDE; IRON; PROTEIN BAX; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSLATION REGULATION;

APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE; CELL LINE, TUMOR; DEFEROXAMINE; DOXORUBICIN; DRUG SYNERGISM; FREE RADICALS; HUMANS; HYDROGEN PEROXIDE; IRON CHELATING AGENTS; MALE; PEPTIDE ELONGATION FACTOR 2; PHENOTYPE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34548754443     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.06.015     Document Type: Article

References (43)

1. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998) 900-905
2. Panjrath G.S., and Jain D. Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging. J. Nucl. Cardiol. 13 (2006) 415-426
3. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., and Kotamraju S. Doxorubicin- induced apoptosis: Implications in cardiotoxicity. Mol. Cell. Biochem. 234-235 (2002) 119-124
4. Swift L.P., Rephaeli A., Nudelman A., Phillips D.R., and Cutts S.M. Doxorubicin-DNA adducts induce a non-topoisomerase ii-mediated form of cell death. Cancer Res. 66 (2006) 4863-4871
5. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin. Drug Saf. 4 (2005) 219-234
6. Barnabe N., Zastre J.A., Venkataram S., and Hasinoff B.B. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radical Biol. Med. 33 (2002) 266-275
7. Le N.T., and Richardson D.R. Potent iron chelators increase the mrna levels of the universal cyclin-dependent kinase inhibitor p21(cip1/waf1), but paradoxically inhibit its translation: A potential mechanism of cell cycle dysregulation. Carcinogenesis 24 (2003) 1045-1058
8. Wagner B.A., Evig C.B., Reszka K.J., Buettner G.R., and Burns C.P. Doxorubicin increases intracellular hydrogen peroxide in PC3 prostate cancer cells. Arch. Biochem. Biophys. 440 (2005) 181-190
9. Nitobe J., Yamaguchi S., Okuyama M., Nozaki N., Sata M., Miyamoto T., Takeishi Y., Kubota I., and Tomoike H. Reactive oxygen species regulate flice inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc. Res. 57 (2003) 119-128
10. Djerbi M., Darreh-Shori T., Zhivotovsky B., and Grandien A. Characterization of the human Flice-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms. Scand. J. Immunol. 54 (2001) 180-189
11. Kelly M.M., Hoel B.D., and Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to trail induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol. Ther. 1 (2002) 520-527
12. Krueger A., Schmitz I., Baumann S., Krammer P.H., and Kirchhoff S. Cellular Flice-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276 (2001) 20633-20640
13. White S.J., Lu P., Keller G.M., and Voelkel-Johnson C. Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol. Ther. 5 (2006) 1618-1623
14. Dever T.E. Gene-specific regulation by general translation factors. Cell 108 (2002) 545-556
15. Wang L., Wang X., and Proud C.G. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am. J. Physiol. Heart Circ. Physiol. 278 (2000) H1056-H1068
16. Ayala A., Parrado J., Bougria M., and Machado A. Effect of oxidative stress, produced by cumene hydroperoxide, on the various steps of protein synthesis. Modifications of elongation factor-2. J. Biol. Chem. 271 (1996) 23105-23110
17. Celis J.E., Madsen P., and Ryazanov A.G. Increased phosphorylation of elongation factor 2 during mitosis in transformed human amnion cells correlates with a decreased rate of protein synthesis. Proc. Natl. Acad. Sci. USA 87 (1990) 4231-4235
18. Horman S., Browne G., Krause U., Patel J., Vertommen D., Bertrand L., Lavoinne A., Hue L., Proud C., and Rider M. Activation of amp-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr. Biol. 12 (2002) 1419-1423
19. Bataller M., and Portugal J. Apoptosis and cell recovery in response to oxidative stress in p53- deficient prostate carcinoma cells. Arch. Biochem. Biophys. 437 (2005) 151-158
20. Siu W.Y., Yam C.H., and Poon R.Y. G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse swiss3t3 cells. FEBS Lett. 461 (1999) 299-305
21. Islaih M., Halstead B.W., Kadura I.A., Li B., Reid-Hubbard J.L., Flick L., Altizer J.L., Thom Deahl J., Monteith D.K., Newton R.K., and Watson D.E. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat. Res. 578 (2005) 100-116
22. Norris J.S., Hyer M.L., Voelkel-Johnson C., Lowe S.L., Rubinchik S., and Dong J.Y. The use of Fas ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr. Gene Ther. 1 (2001) 123-136
23. Voelkel-Johnson C. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biol. Ther. 2 (2003) 283-290
24. Poukkula M., Kaunisto A., Hietakangas V., Denessiouk K., Katajamaki T., Johnson M.S., Sistonen L., and Eriksson J.E. Rapid turnover of c-flipshort is determined by its unique C- terminal tail. J. Biol. Chem. 280 (2005) 27345-27355
25. Arora S., Yang J.M., and Hait W.N. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res. 65 (2005) 3806-3810
26. Patel J., McLeod L.E., Vries R.G., Flynn A., Wang X., and Proud C.G. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur. J. Biochem. 269 (2002) 3076-3085
27. Lee V., Randhawa A.K., and Singal P.K. Adriamycin-induced myocardial dysfunction in vitro is mediated by free radicals. Am. J. Physiol. 261 (1991) H989-H995
28. Fornari Jr. F.A., Jarvis W.D., Grant S., Orr M.S., Randolph J.K., White F.K., Mumaw V.R., Lovings E.T., Freeman R.H., and Gewirtz D.A. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ. 5 (1994) 723-733
29. Tan M., Gallegos J.R., Gu Q., Huang Y., Li J., Jin Y., Lu H., and Sun Y. Sag/Roc-SCFbeta- TRCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 8 (2006) 1042-1054
30. Cao X., Deng X., and May W.S. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 102 (2003) 2605-2614
31. Zhang L., Zhu H., Teraishi F., Davis J.J., Guo W., Fan Z., and Fang B. Accelerated degradation of caspase-8 protein correlates with trail resistance in a DLD1 human colon cancer cell line. Neoplasia 7 (2005) 594-602
32. Nesterov A., Ivashchenko Y., and Kraft A.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21 (2002) 1135-1140
33. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., Marusawa H., Zou H., Armstrong R., Matsuzawa S., Salvesen G.S., Reed J.C., and Altieri D.C. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 279 (2004) 34087-34090
34. Zhao J., Tenev T., Martins L.M., Downward J., and Lemoine N.R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113 Pt 23 (2000) 4363-4371
35. Purdom S., and Chen Q.M. Epidermal growth factor receptor-dependent and -independent pathways in hydrogen peroxide-induced mitogen-activated protein kinase activation in cardiomyocytes and heart fibroblasts. J. Pharmacol. Exp. Ther. 312 (2005) 1179-1186
36. Kotamraju S., Chitambar C.R., Kalivendi S.V., Joseph J., and Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: Role of oxidant-induced iron signaling in apoptosis. J. Biol. Chem. 277 (2002) 17179-17187
37. Tebbi C.K., London W.B., Friedman D., Villaluna D., De Alarcon P.A., Constine L.S., Mendenhall N.P., Sposto R., Chauvenet A., and Schwartz C.L. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric hodgkin's disease. J. Clin. Oncol. 25 (2007) 493-500
38. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P.J., Achanta G., Arlinghaus R.B., Liu J., and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10 (2006) 241-252
39. Zhang Y., Gu J., Zhao L., He L., Qian W., Wang J., Wang Y., Qian Q., Qian C., Wu J., and Liu X.Y. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res. 66 (2006) 4291-4298
40. Perez-Cruz I., Carcamo J.M., and Golde D.W. Caspase-8 dependent trail-induced apoptosis in cancer cell lines is inhibited by vitamin c and catalase. Apoptosis 12 (2007) 225-234
41. Naganuma A., Satoh M., and Imura N. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn. J. Cancer Res. 79 (1988) 406-411
42. Satoh M., Naganuma A., and Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci. 67 (2000) 627-634
43. Malarkodi K.P., Sivaprasad R., and Varalakshmi P. Effect of lipoic acid on the oxidoreductive status of red blood cells in rats subject to oxidative stress by chronic administration of adriamycin. Hum. Exp. Toxicol. 23 (2004) 129-135